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Coronary Artery Disease and Infection
with Chlamydia Pneumonia
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SUMMARY
The association between chlamydia pneumonia and coronary artery
disease is well documented, however less is known about the correlation
between chlamydia pneumonia infection and blood inflammatory markers or
lipid levels. In 100 patients with proven coronary artery disease (25 females,
61.0 ± 4.0 years old), and 60 healthy volunteer control cases (15 females, 60.6
± 3.4 years old), anti chlamydia pneumonia IgG, blood lipid, C-reactive protein
and fibrinogen levels were detected. In cases with coronary artery disease
seropositivity for IgG antibodies to chlamydia pneumonia (74% versus 34%, p
< 0.0001), C-reactive protein (mg / l) (2.8 ± 0.6 versus 1.4 ± 0.6, p < 0.0001),
fibrinogen (mg / dl) (317.4 ± 38.2 versus 256.2 ± 34.5, p < 0.0001), triglyceride
(mg / dl) (217.5 ± 39.0 versus 191.0 ± 25.9, p < 0.0001), LDL-cholesterol (mg
/ dl) (126.9 ± 19.2 versus 110.6 ± 19.5, p < 0.0001) levels and total cholesterol
/ HDL-cholesterol ratio (7.7 ± 1.8 versus 4.4 ± 1.2, p < 0.0001) were higher but
the level of HDL-cholesterol (mg / dl) (26.4 ± 6.7 versus 47.0 ± 11.2, p <
0.0001) was lower. The levels of total cholesterol did not differ between the
two groups (p = 0.9). Levels of triglyceride (r = 0.60, p < 0.00001),
LDL-cholesterol (r = 0.27, p = 0.0004), C-reactive protein (r = 0.69, p <
0.00001), fibrinogen (r = 0.60, p < 0.00001) and total cholesterol / HDL-
cholesterol ratio (r = 0.74, p < 0.00001) had a direct relation, but the level of
HDL-cholesterol had a negative (r = − 0.80, p < 0.00001) relation with the
seropositivity for chlamydia pneumonia.
As a result, seropositivity for IgG antibodies to chlamydia pneumonia is
considered as a risk factor for coronary artery disease by its association with the
atherogenic lipid profile and procoagulant activity. (Jpn Heart J 2000; 41:
165-172)
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CHLAMYDIA pneumonia has been associated with coronary artery diseaseand myocardial infarction in several seroprevalence studies,1-7) and one
prospective cohort study.8) This link has become more persuasive by the
identification of chlamydia pneumonia (CP) elementary bodies in atherosclerotic
plaques and fatty streaks in autopsy cases from the aorta and coronary arteries9,10)
from coronary atherectomy11) and from endarterectomy specimens from carotid
arteries.12,13) The organism is rarely found in vascular specimens from non-
atherosclerotic patients or those with nonatherogenic arteriopathy.11,13-19)
Various mechanisms have been suggested whereby infection with CP may
affect the risk of cardiovascular disease. Animal models have shown that CP
easily gains access to the vascular system following pulmonary infection.20)
Infection of endothelial or smooth muscle cells in vessel walls may occur21)
resulting in local inflammation and fibrosis and subsequent atheroma formation.
Alternatively repeated or persistent CP infection may stimulate the production of
proinflammatory cytokines22) which may increase the risk of cardiovascular
disease23,24) by disturbing the basal thromboresistant function of vascular
endothelial cells25) inhibiting endothelium derived relaxing factor,25,26) or affecting
smooth muscle cell contractility27) or induction of an atherogenic lipid profile.28,29)
In this prospective case controlled study blood samples of patients with
coronary artery disease (CAD) were analysed for the presence of IgG antibodies
against CP and its relation with levels of blood lipids and inflammatory markers
was studied.
MATERIALS AND METHODS
We studied 100 consecutive patients with angiographically proven coronary
artery disease (25 females, ages 61.0 ± 4.0 years) and all were stable at the time of
study. The control group consisted of 60 healthy volunteers (15 females, ages
60.6 ± 3.4 years). Their ages, all gender, body mass indexes, smoking and
alcohol habits were well matched to each other. All of the patients had
angiographic documentation of a coronary stenosis ≥ 50 % of at least one
coronary artery, and all without recent or remote myocardial infarction. The
control group was chosen from healthy volunteers not having any cardiac or
inflammatory disease. All underwent total blood count, resting elect-
rocardiography and exercise stress electrocardiography to exclude any in-
flammatory or ischemic heart disease.
Exclusion criteria included: Recent myocardial infarction, stable or unstable
angina pectoris, an immunological disease, and an infectious or inflammatory
disease in the last 6 months, liver insufficiency, primary myocardial disease, and
endomyopericarditis.
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Height and weight were measured and body mass index (BMI) determined,
a blood sample (not fasting) taken, centrifuged and separated within four hours.
Serum from all subjects was analysed for total cholesterol (by an enzymatic
colorimetric method), HDL-cholesterol (by a lipoprotein precipitation method),
triglycerides (TG) (by an enzymatic colorimetric method), LDL-cholesterol
(calculated according to Fridewald formula) and C-reactive protein (CRP) levels.
Plasma was analysed for fibrinogen levels (photo-optically). The ratio of total
cholesterol to HDL-cholesterol was then determined. Serum from all cases was
analysed for the presence of anti CP antibodies. The chlamydia MIF
(microimmunofluorescence) assay was used to detect the presence of IgG
antibodies to antigens from CP at a serum dilution of 1: 64.
Statistics: Analysis was done using a 2-sample independent-t test and chi-square
test for comparison of 2 groups. Pearson’s correlation analysis was used to show
the relation between variables and anti CP IgG seropositivity and presence of
coronary artery disease. A p value of < 0.05 was accepted as statistically
significant.
RESULTS
The demographic variables of the groups are shown in Table I. This report
was based on sera from 160 subjects, 100 of whom were patients with proven
CAD at the stable and chronic stage and 60 were healthy volunteers.
Seropositivity for anti CP IgG was 78 % for the patient and 34 % for the control
groups (p < 0.0001) (Table II) and were not correlated with age, sex, BMI, blood
pressure levels, smoking habit or alcohol consumption.
In the CAD group TG (mg / dl) (217.5 ± 39.0 versus 191.0 ± 25.9, p <
0.0001), LDL-cholesterol (mg / dl) (126.9 ± 19.2 versus 110.6 ± 19.5, p <
0.0001), CRP (mg / l) (2.8 ± 0.6 versus 1.4 ± 0.6, p < 0.0001), and fibrinogen
(mg / dl) (317.4 ± 38.2 versus 256.2 ± 34.5, p < 0.0001) levels and the total
cholesterol / HDL-cholesterol ratio (7.7 ± 1.8 versus 4.4 ± 1.2, p < 0.0001) were
higher than the control cases, but the level of HDL-cholestorol (mg / dl) (26.4 ±
6.7 versus 47.0 ± 11.2, p < 0.0001) was lower. The level of total cholesterol did
not differ between the groups (p = 0.9) (Table II). While the levels of TG (r =
0.60, p < 0.00001), LDL-cholesterol (r = 0.27, p = 0.0004), CRP (r = 0.69, p <
0.00001), and fibrinogen (r = 0.60, p < 0.00001) and the total cholesterol /
HDL-cholesterol ratio (r = 0.74, p < 0.00001) showed a direct relation with the
presence of anti CP IgG antibody, the HDL-cholesterol level showed an inverse
relation (r = − 0.80, p < 0.00001). We also observed a positive relation for TG (r
= 0.34, p < 0.0001), LDL-cholesterol (r = 0.38, p < 0.0001), CRP (r = 0.73, p <
0.0001), fibrinogen (r = 0.62, p < 0.0001), and total cholesterol / HDL-cholesterol
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Table I. Baseline Characteristics of the Study Groups
Variables CAD (n = 100) Control (n = 60) p
Age (years)
Gender (% female)
BMI (kg / m2)
Smoking ratio (%)
Alcohol (%)
Hypertension (%)
Diabetes mellitus (%)
Hypertension ± Diabetes mellitus (%)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
61.0 ± 4.0
25
24.9 ± 1.4
42
8
35
20
13
129.1 ± 17.5
78.9 ± 10.7
60.6 ± 3.4
25
24.7 ± 1.4
36
3
0
0
0
118.0 ± 8.6
72.9 ± 5.7
0.5
1
0.5
0.53
0.4
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
Table II. Laboratory Findings of the Study Groups
Variable CAD (n = 100) Control (n = 60) p
Anti CP IgG seropositivity (%)
Total cholesterol (mg / dl)
HDL-cholesterol (mg / dl)
LDL-cholesterol (mg / dl)
TG (mg / dl)
Total cholesterol / HDL
CRP (mg / l)
Fibrinogen (mg / dl)
74
196.7 ± 20.0
26.4 ± 6.7
126.9 ± 19.2
217.5 ± 3.9
7.7 ± 1.8
2.8 ± 0.6
317.4 ± 38.4
34
196.0 ± 21.0
47.0 ± 11.2
110.6 ± 19.5
191.0 ± 25.9
4.4 ± 1.2
1.4 ± 0.6
256.2 ± 34.5
< 0.0001
0.9
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
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(r = 0.70, p < 0.0001), and a negative relation for HDL-cholesterol (r = − 0.75, p
< 0.0001) with the presence of CAD (Table III). The correlations between
variables in the presence of anti CP IgG antibodies according to the presence or
absence of CAD are presented in Table IV. Similar correlations for the variables
in the two different groups for the presence of anti CP IgG antibodies were
observed. In other words, positive correlations for TG, LDL-cholesterol, CRP,
fibrinogen, total / cholesterol / HDL - cholesterol, and a negative relation for
HDL-cholesterol with the presence of anti CP IgG antibodies were observed in
the two groups.
DISCUSSION
The ability of several microorganisms (Helicobacter pylori, Chlamydia
pneumonia and the agents of dental infections) to cause chronic infections and to
be related to both CAD and cardiovascular risk factors has been recently proved.5)
Chronic CP infection might contribute to the development of coronary heart
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Table III. Correlations between Laboratory Findings and Anti CP IgG Seropositivity and CAD According to
Pearson’s Correlation Analysis
Variable
Anti CP IgG
seropositivity
CAD
Total Cholesterol r
p
HDL-cholesterol r
p
LDL-cholesterol r
p
TG r
p
Total cholesterol / HDL r
p
CRP r
p
Fibrinogen r
p
− 0.01
0.83
− 0.80
< 0.00001
0.27
0.0004
0.60
0.00001
0.74
< 0.00001
0.69
< 0.00001
0.60
< 0.00001
0.007
0.92
− 0.75
< 0.0001
0.38
< 0.0001
0.34
< 0.0001
0.70
< 0.0001
0.73
< 0.0001
0.62
< 0.0001
Table IV. Correlation between Variables and Anti CP IgG Seropositivity for the CAD and Control Groups
Variables
CAD and Anti CP IgG
seropositivity
Control cases and Anti CP
IgG seropositivity
Total cholesterol r
p
HDL-cholesterol r
p
LDL-cholesterol r
p
TG r
p
Total cholesterol / HDL r
p
CRP r
p
Fibrinogen r
p
0.04
0.66
− 0.82
< 0.0001
0.35
< 0.0001
0.61
< 0.0001
0.76
< 0.0001
0.71
< 0.0001
0.62
< 0.0001
0.11
0.38
− 0.79
< 0.0001
0.39
0.002
0.57
< 0.0001
0.83
< 0.0001
0.74
< 0.0001
0.79
< 0.0001
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disease. CP can multiply in macrophages and endothelial cells.30-32) Immune
complexes might be deposited on the vessel wall creating local inflammatory and
procoagulant changes.33) The host response to infectious agents usually involves a
change in the process of hepatic protein synthesis. The cytokine interleukin 6
may mediate much of this switch from the production of housekeeping proteins
such as albumin to greater synthesis of proteins collectively known as acute phase
reactants, some of which may influence atherogenesis. Augmented production of
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fibrinogen and plasminogen activator inhibitor during the acute phase response
could promote thrombosis. Increased production of serum amyloid A protein can
alter the potential function of HDL in cholesterol export from atheromatous
lesions and in coronary risk. Also systemic infections can decrease HDL
cholesterol concentrations.34) In our study acute phase reactants like CRP and
fibrinogen were found to be increased in CAD patients compared to control cases,
and showed a direct correlation with the seropositivity for IgG antibodies to CP.
In addition, we found increased TG, LDL levels and total cholesterol /
HDL-cholesterol ratio in CAD, showing a positive correlation with anti CP IgG
positivity for all cases, and low HDL-cholesterol levels in CAD, showing a
negative correlation with the seropositivity for anti CP IgG for all cases. The
mechanisms of these changes in cases with seropositivity for IgG antibodies to CP
might be explained as above. Our patient group consisted of patients with chronic
stable coronary heart disease and seropositivity for IgG antibodies to CP might be
strongly due to the chronic persistent infection, as explained before by Mazzoli, et
al,35) Murray, et al,36) and Laurila, et al,28) who also found increased total
cholesterol and decreased HDL-cholesterol levels in their coronary heart disease
group, first showing a direct and second an inverse relation with the seropositivity
for IgG antibodies to chlamydia pneumonia.36) This was consistent with our
findings, except for the total cholesterol levels. In our study the level of total
cholesterol did not exhibit any difference between the two groups.
The most commonly reported infection induced lipid abnormalities in man
and experimental animals have been decreased HDL-cholesterol and raised
triglycerides and very low density lipoprotein.37-39) These effects are part of the
acute phase response and appear to be mediated by cytokines such as tumor
necrosis factor, interleukin-1 and interleukin-6,38) and have been observed in
persons with serological evidence of CP infection.28) The effect of infection on
total and LDL-cholesterol is less clear. But it has been reported in humans and
primates that total and LDL-cholesterol values decrease in severe bacterial
infections.37,39,40) These changes are seen in acute infections, but the lipid
response to a chronic infection could be different from an acute one with some
similarities like in our cases who showed decreased HDL-cholesterol levels and
increased TG levels. The presence of normal but relatively high levels of CRP
and fibrinogen in our patient group may be a nonspecific phenomenon reflecting
cytokine mediated hepatic production triggered by most forms of inflammation,
infection or tissue injury.
The results of the present study demonstrate that chronic or acute infection
with chlamydia pneumonia may mediate the progression of atherosclerotic
coronary heart disease by altering the blood lipid profile and increasing blood
procoagulant activity.
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